Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403256 | 0.76 | ALDH1A1 (0.32) | AGBL2ALDH1A1 | |
| SCHEMBL2120862 | 0.76 | ALDH1A1 (0.32) | AGBL2ALDH1A1 | |
| SCHEMBL2177580 | 0.75 | RAB9A (0.32) | AGBL2 | |
| SCHEMBL394514 | 0.74 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL944873 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL20554214 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2177694 | 0.74 | SMN1; SMN2 (0.33) | AGBL2ALDH1A1 | |
| SCHEMBL1144277 | 0.74 | AGBL2 (0.33) | AGBL2ALDH1A1 | |
| SCHEMBL2177005 | 0.71 | POLB (0.38) | AGBL2ALDH1A1 | |
| SCHEMBL2176668 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | claimed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | claimed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | claimed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | claimed |
| WO-2003033502-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-04-24 | — | — | WO | claimed |
| EP-0535548-B1 | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL IND LTD (JP) | 2001-11-21 | — | — | EP | claimed |
| US-6162798-A | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2000-12-19 | — | — | US | claimed |
| CN-1102644-A | Condensed pyridine type mevalonolactone intermediate and process for its production | SAGAMI CHEM RES (JP) | 1995-05-17 | — | — | CN | claimed |
| WO-1995011898-A1 | CONDENSED PYRIDINE TYPE MEVALONOLACTONE INTERMEDIATE AND PROCESS FOR ITS PRODUCTION | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-05-04 | — | — | WO | claimed |
| EP-0339358-B1 | Pyrazolopyridine type mevalonolactones | NISSAN CHEMICAL IND LTD (JP) | 1994-07-13 | — | — | EP | claimed |
| EP-0535548-A1 | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-04-07 | — | — | EP | claimed |
| US-5024999-A | Anti-hyperlipidemia, anti-atherosclerosis agents | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-06-18 | — | — | US | claimed |
| EP-0339358-A1 | Pyrazolopyridine type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-11-02 | — | — | EP | claimed |
| WO-1989010365-A1 | PYRAZOLOPYRIDINE TYPE MEVALONOLACTONES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | AGBL2 3929/4885RAPGEF4 2340/4885ALDH1A1 570/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | AGBL2 3152/4885RAPGEF4 2524/4885ALDH1A1 308/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | AGBL2 614/4885RAPGEF4 2618/4885ALDH1A1 472/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | AGBL2 3948/4885RAPGEF4 2131/4885ALDH1A1 552/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | AGBL2 619/4885RAPGEF4 2580/4885ALDH1A1 450/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | AGBL2 3152/4885RAPGEF4 2524/4885ALDH1A1 308/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | AGBL2 3929/4885RAPGEF4 2340/4885ALDH1A1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.